ATC Group: A02BC05 Esomeprazole

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A02BC05 in the ATC hierarchy

Level
Code
Title
1
Alimentary tract and metabolism
2
Drugs for acid related disorders
3
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
4
Proton pump inhibitors
5
A02BC05
Esomeprazole

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
30 mg
PAREN - Parenteral
30 mg

Active ingredients in A02BC05

Active Ingredient
Description

Esomeprazole is the S-isomer of omeprazole and reduces gastric acid secretion through a specific targeted mechanism of action. Esomeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cell, where it inhibits the enzyme H+ K+ -ATPase – the acid pump and inhibits both basal and stimulated acid secretion.

Medicines in this ATC group

Drug
Countries

Finland

Tunisia

South Africa

Ecuador

Singapore Spain

Ecuador

Ecuador

South Africa

South Africa

Austria

Estonia Lithuania

Ecuador

Hong Kong Poland Romania Singapore Spain ...

Ireland Singapore

United Kingdom

Ecuador

South Africa

Turkey

Singapore

South Africa

Estonia Lithuania

Lithuania

Brazil

Turkey

Brazil

Turkey

Tunisia

Tunisia

Ecuador

Ecuador Tunisia

Hong Kong

Brazil South Africa

Ecuador

Brazil

Hong Kong

Italy Turkey

Ecuador

Australia

Turkey

Tunisia

South Africa

Turkey

Ecuador Hong Kong Singapore

Estonia

Estonia Lithuania

South Africa

Turkey

Cyprus Lithuania

Ecuador

Ecuador

Ecuador

Brazil

Turkey

South Africa

United Kingdom

Poland Romania

South Africa

France Tunisia

Tunisia

Singapore

Hong Kong

Hong Kong

South Africa

Lithuania Poland Tunisia

Brazil

South Africa

South Africa

Hong Kong

South Africa

Australia Ireland

Turkey

South Africa

South Africa

South Africa

South Africa

Australia Austria Brazil Canada Cyprus ...

Estonia Lithuania South Africa

Australia

South Africa Turkey

Hong Kong

Tunisia

Australia

Hong Kong

Ecuador

South Africa

Tunisia

Tunisia

Lithuania

Brazil Ecuador Singapore

Hong Kong

Tunisia

South Africa

South Africa

South Africa

Ecuador

Ecuador

South Africa

Hong Kong United Kingdom

Brazil

Related product monographs

Title
Type
Country
Summary of Product Characteristics (SPC)
IE
Summary of Product Characteristics (SPC)
IE
Summary of Product Characteristics (SPC)
UK
Summary of Product Characteristics (SPC)
UK
Summary of Product Characteristics (SPC)
UK
Medication Package Insert (MPI)
ZA
Summary of Product Characteristics (SPC)
UK